Skip to main content

BCTX

Stock
Health Care
Biotechnology

Performance overview

BCTX Price
Price Chart

Forward-looking statistics

Beta
0.58
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Company info

SectorHealth Care
IndustryBiotechnology
Employees14
Market cap$25.4M

Fundamentals

Enterprise value$7.0M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.69
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$409K
Avg trading volume (10 day)$332K
Put-call ratio

Macro factor sensitivity

Growth-7.0
Credit+10.2
Liquidity+3.7
Inflation-11.6
Commodities-6.0
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio-7.46
Price to sales
P/E Ratio-7.46
Enterprise Value to Revenue
Price to book1.54

Upcoming events

Next earnings dayMarch 13, 2025
Next dividend day
Ex. dividend day

News

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell Therapeutics Corp. BCTX confirmed on Thursday that it has sustained a complete resolution of the lung metastasis, first reported in February 2025, two months after the initial treatment in the ongoing Phase 1/2 Bria-OTS study.

Benzinga (April 24, 2025)
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research (February 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free